Cyclin-dependent Kinase Inhibitor In Acute Renal Failure

急性肾衰竭中的细胞周期蛋白依赖性激酶抑制剂

基本信息

  • 批准号:
    7569026
  • 负责人:
  • 金额:
    $ 22.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-08-01 至 2011-01-31
  • 项目状态:
    已结题

项目摘要

Our long-term objective is to prevent and/or treat acute renal failure. We showed that activation of the gene for the p21 cyclin-dependent kinase (cdk) inhibitor ameliorated renal failure after cisplatin administration and renal ischemia/reperfusion. After these injuries, comparing p21(+/+) with p21(-/-) mice, there was significantly less cellular damage, including both necrosis and apoptosis, less functional kidney failure, and less mortality in the p21(+/+) population. The mechanism was directly dependent on the role of p21 as a regulator of the cell cycle. We now find that induction of p21 using an adenoviral vector before cisplatin exposure completely protected mouse kidney proximal tubule cells in vitro from cytotoxicity. Similarly, pretreatment of kidney cells with different pharmacologic cdk2 inhibitors or with a histone deacetylase (HDAC) inhibitor known to induce p21 was also protective. We extended these findings by showing that a cdk2 inhibitory drug, with a spectrum of activity similar to p21, also protected kidney function and cell morphology in vivo from cisplatin-induced renal injury. We hypothesize that cdk2 inhibitors protect kidney cells from cisplatin-induced toxicity by inhibiting cell death pathways activated by cisplatin exposure. Furthermore, we hypothesize that cdk2 inhibitors will be useful to prevent and treat acute renal failure. We have developed aims that will determine the mechanism of cdk inhibitor protection in vitro and in vivo and provide initial steps to utilize cdk inhibitors to ameliorate cisplatin-induced renal failure. Our first specific aim is to determine the mechanism of cdk inhibitor protection. We will confirm that cdk inhibitor protection is dependent on repressing cdk2 activity. We will determine cdk2 localization and the localization of cdk2-p21 interaction. We will determine the cell death pathway(s) inhibited by cdk2 inhibitors, and for each death pathway inhibited by cdk2 inhibitors, determine whether it is activated by cisplatin. Our second specific aim is to determine conditions and mechanisms of protection by cdk2 inhibitors in vivo. We will determine whether cdk2 knock-out mice are protected from cisplatin nephrotoxicity, and whether the samefragment of p21 that protects in vitro also protects in vivo. We will confirm purvalanol in vivo protection and refine the conditions for its action.
我们的长期目标是预防和/或治疗急性肾功能衰竭。我们展示了激活

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER M. PRICE其他文献

PETER M. PRICE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER M. PRICE', 18)}}的其他基金

Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
Cdk2 底物磷酸化对急性肾损伤的生物学效应
  • 批准号:
    8597416
  • 财政年份:
    2011
  • 资助金额:
    $ 22.12万
  • 项目类别:
Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
Cdk2 底物磷酸化对急性肾损伤的生物学效应
  • 批准号:
    8260111
  • 财政年份:
    2011
  • 资助金额:
    $ 22.12万
  • 项目类别:
Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
Cdk2 底物磷酸化对急性肾损伤的生物学效应
  • 批准号:
    8141668
  • 财政年份:
    2011
  • 资助金额:
    $ 22.12万
  • 项目类别:
Biologic Effects of Cdk2 Substrate Phosphorylation on Acute Kidney Injury
Cdk2 底物磷酸化对急性肾损伤的生物学效应
  • 批准号:
    8398965
  • 财政年份:
    2011
  • 资助金额:
    $ 22.12万
  • 项目类别:
CYCLIN DEPENDENT KINASE INHIBITOR IN ACUTE RENAL FAILURE
细胞周期蛋白依赖性激酶抑制剂治疗急性肾衰竭
  • 批准号:
    6177901
  • 财政年份:
    1998
  • 资助金额:
    $ 22.12万
  • 项目类别:
Cyclin-dependent Kinase Inhibitor in Acute Renal Failure
急性肾衰竭中的细胞周期蛋白依赖性激酶抑制剂
  • 批准号:
    8477648
  • 财政年份:
    1998
  • 资助金额:
    $ 22.12万
  • 项目类别:
CYCLIN DEPENDENT KINASE INHIBITOR IN ACUTE RENAL FAILURE
细胞周期蛋白依赖性激酶抑制剂治疗急性肾衰竭
  • 批准号:
    6381236
  • 财政年份:
    1998
  • 资助金额:
    $ 22.12万
  • 项目类别:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
急性肾衰竭中的细胞周期蛋白依赖性激酶抑制剂
  • 批准号:
    7766238
  • 财政年份:
    1998
  • 资助金额:
    $ 22.12万
  • 项目类别:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
急性肾衰竭中的细胞周期蛋白依赖性激酶抑制剂
  • 批准号:
    7379947
  • 财政年份:
    1998
  • 资助金额:
    $ 22.12万
  • 项目类别:
Cyclin-dependent Kinase Inhibitor In Acute Renal Failure
急性肾衰竭中的细胞周期蛋白依赖性激酶抑制剂
  • 批准号:
    7045861
  • 财政年份:
    1998
  • 资助金额:
    $ 22.12万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 22.12万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 22.12万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了